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Aim Long QT syndrome (LQTS) is a cardiac channelopathy predisposing to ventricular arrhythmias and sudden cardiac
death. Since current therapies often fail to prevent arrhythmic events in certain LQTS subtypes, new therapeutic





We investigated the effects of DHA in wild type (WT) and transgenic long QT Type 1 (LQT1; loss of IKs), LQT2
(loss of IKr), LQT5 (reduction of IKs), and LQT2–5 (loss of IKr and reduction of IKs) rabbits. In vivo ECGs were
recorded at baseline and after 10mM/kg DHA to assess changes in heart-rate corrected QT (QTc) and short-term
variability of QT (STVQT). Ex vivo monophasic action potentials were recorded in Langendorff-perfused rabbit
hearts, and action potential duration (APD75) and triangulation were assessed. Docosahexaenoic acid significantly
shortened QTc in vivo only in WT and LQT2 rabbits, in which both a- and b-subunits of IKs-conducting channels
are functionally intact. In LQT2, this led to a normalization of QTc and of its short-term variability.
Docosahexaenoic acid had no effect on QTc in LQT1, LQT5, and LQT2–5. Similarly, ex vivo, DHA shortened
APD75 in WT and normalized it in LQT2, and additionally decreased AP triangulation in LQT2.
...................................................................................................................................................................................................
Conclusions Docosahexaenoic acid exerts a genotype-specific beneficial shortening/normalizing effect on QTc and APD75 and
reduces pro-arrhythmia markers STVQT and AP triangulation through activation of IKs in LQT2 rabbits but has no
effects if either a- or b-subunits to IKs are functionally impaired. Docosahexaenoic acid could represent a new
genotype-specific therapy in LQT2.
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Introduction
Long QT syndrome (LQTS) is a genetic channelopathy with impaired
cardiac repolarization that can lead to Torsades de Pointes (TdP)
ventricular tachycardias, arrhythmic syncopes, or sudden cardiac
death (SCD).1 In >80% of LQTS patients one of the main ventricular
repolarizing potassium currents, IKs and IKr, is reduced or absent due
to loss-of-function mutations in genes encoding for the correspond-
ing potassium channel subunits such as a-subunit to IKs-conducting
potassium channel (KCNQ1) [long QT Type 1 (LQT1)], a-subunit to
IKr-conducting potassium channel (KCNH2) [long QT Type 2
(LQT2)], or b-subunit to IKs-conducting potassium channel (KCNE1)
[long QT Type 5 (LQT5)].2 Beta-blockers, such as nadolol or pro-
pranolol, represent the first-line therapy in LQT1 and 2, but offer a
rather unspecific protection from arrhythmic events by reducing the
triggering sympathetic stimuli. Reports suggest a 5-year risk of cardiac
events up to 32% in symptomatic LQTS patients despite an appropri-
ate beta-blocker therapy.3 Therefore, there is still an urgent need for
new therapeutic strategies, which reduce the incidence of arrhyth-
mias in LQTS.
Docosahexaenoic acid (DHA) is an omega-3 fatty acid of marine
origin, which contributes to various biological activities such as (i) the
modulation of gene expression, (ii) the regulation of the physical
properties of membranes, and (iii) the production of eicosanoids.
Importantly, DHA was described to increase IKs currents and may
thereby affect cardiac repolarization.4 Interactions between DHA
and the channel complex constituted by KCNQ1 and KCNE1 in
guinea pig cardiomyocytes have been studied by Moreno et al.,5 sug-
gesting that DHA exerts an activating effect on IKs by altering the re-
ciprocal electrostatic interactions between KCNQ1 and KCNE1. In
this regard, Liin et al.4 suggested that KCNE1 may influence the sensi-
bility of KCNQ1 to DHA or other fatty acids due to a protonation of
KCNQ1. Apart from cellular electrophysiology experiments, recent
ex vivo whole heart and in vivo experiments in guinea pig models dem-
onstrated that DHA may indeed shorten cardiac repolarization/QT
interval in healthy and drug-induced LQTS guinea pig models.6
In this study, we take these experiments a step further, investigat-
ing potentially beneficial shortening effects on QT and action poten-
tial duration (APD) in genetic rabbit models for LQTS, also
investigating potential genotype-specific effects. The rabbit is a spe-
cies that plays an important role in LQTS-related arrhythmia re-
search: the function and gating kinetics of the underlying cardiac
repolarizing ion-channels/currents, the shape of action potential
(AP), and cardiac responses to pharmacological interventions show
very close resemblance to human cardiac physiology.7 Transgenic
rabbit models for various subtypes of LQTS have been developed
and mimic the human disease phenotypes.8,9
The LQT1 and LQT2 rabbit models lack IKs or IKr currents, respec-
tively due to loss-of-function mutations in KCNQ1 or KCNH28; LQT5
rabbits have reduced IKs current due to a mutation in the beta-
subunit KCNE19; and LQT2–5 rabbits lack IKr and have reduced activ-
ity of IKs.
10 These LQTS rabbit models thus provide the opportunity
to look into the effects of DHA on ventricular cardiac repolarization
in a genotype-specific fashion.
Methods
A more detailed method section is found in Supplementary material
online.
Ethical aspects
All animal experiments were performed in compliance with EU legislation
(directive 2010/63/EU) and the German (TierSchG and TierSchVersV)
animal welfare laws, after approval by the local Institutional Animal Care
and Use Committees in Germany (Regierungspraesidium Freiburg; ap-
proval number G14/111). The experimental use of Xenopus laevis was
reviewed and approved by the regional board of ethics in Linköping,
Sweden (Case no 1941). Animal housing and handling were in accor-
dance with good animal practice as defined by the Federation of
European Laboratory Animal Science Association. Animal studies were
reported in compliance with the ARRIVE guidelines.
Rabbit models
The study was conducted on wild type (New Zealand White, WT,
n = 11) and different transgenic LQTS rabbit models overexpressing hu-
man mutant KCNQ1-Y315S (LQT1, lack of IKs, n = 9), KCNH2-G628S
(LQT2, lack of IKr, n = 11), KCNE1-G52R (LQT5, impaired IKs, n = 12) and
KCNH2-G628S þ KCNE1-G52R (LQT2–5, lack of IKr and impaired IKs,
n = 12) in the heart.8,9 Both male and female animals were equally in-
cluded in the study.
Telemetric ECG monitoring
To study the potential beneficial genotype-specific repolarization short-
ening effect of DHA in awake, free-moving, non-sedated rabbits in vivo, 6
WT, 8 LQT1, 6 LQT2, 8 LQT2–5, and 8 LQT5 rabbits were subjected to
subcutaneous telemetric ECG transmitter implantations as described.10.
24-H telemetric ECG recordings (representing standard ECG limb leads
I–III) were carried out at baseline (drug-free) and following 10mM/kg BW
IM administration of DHA on the subsequent day. Conventional ECG
parameters (RR, PR, QT, and QTc intervals) were measured. At baseline,
pairs of RR and QT intervals were assessed every 30 min as averaged val-
ues over 5 s to collect in total 48 QT-RR pairs for each animal. Similarly,
ECGs were analysed within the first 90 min following the administration
of DHA (starting at 5 min post-injection at which time-point DHA effects
were already observed) every 4–5 min to obtain at least 20 datasets of
RR, QT, PR, and QRS values. For each rabbit, an individual heart rate cor-
rection formula was used to calculate QTc. The individual correction for-
mula was created by plotting the baseline QT and RR pairs (48 pairs for
What’s new?
• IKs-activator docosahexaenoic acid shortens QTc/APD75 and
reduces short-term variability of QT in transgenic long QT
Type 2 (LQT2) and in wild-type rabbits.
• This docosahexaenoic acid (DHA) effect leads to a complete
normalization of QT, STVQT, and APD75 in LQT2.
• In contrast, DHA does not exert any relevant effects on
ventricular repolarization in transgenic LQT1, LQT5, and
LQT2–5 rabbits with impaired IKs function.
• These genotype-specific effects of DHA on repolarization
suggest that both a- and b-subunits to IKs (KCNQ1 and
KCNE1) need to be functionally intact for IKs-activation by
DHA.
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each rabbits) on a Cartesian co-ordinate system and fitting a linear regres-
sion curve. The steepness (a) of the acquired individual QT-RR regres-
sion curve [QT (y) = aRR (x)þ b] was used for the individual heart rate
correction formula [QTc = QTa(RR250)].10
In vivo 12-lead ECG recording in
anaesthetized rabbits
To study DHA effects in vivo, 12-lead ECGs were recorded at baseline
and (within 20 min) after IV administration of 10mM/kg BW DHA in WT
(n = 6), LQT1 (n = 8), LQT2 (n = 5), LQT 2–5 (n = 4), and LQT5 (n = 7)
rabbits anaesthetized with ketamine (12.5 mg/kg BW) and xylazine
(3.75 mg/kg BW) IM. All parameters were stable within 10–15 min after
DHA bolus. We analysed DHA effects in the stable phase at 20 min post-
bolus. DHA effects on conventional ECG parameters and on pro-
arrhythmia markers such as QT dispersion and short-term QT variabil-
ity11 were assessed. The heart rate correction of the QT was performed
as described in Telemetric ECG monitoring section.
Monophasic action potential recording
To investigate the effect of DHA ex vivo, monophasic action potentials
(MAP) were recorded in Langendorff-perfused WT (n = 7), LQT1
(n = 7), LQT2 (n = 6), LQT 2–5 (n = 9), and LQT5 (n = 9) rabbit hearts as
described before.10 The duration of the MAPs at 75% of repolarization as
well as the MAP triangulation (APD90–APD30)—a marker of arrhythmo-




Oocytes were isolated from the African claw frog X. laevis through in-
house frog surgery, following RNA injection and two-electrode voltage-
clamp experiments as described in detail.12,13 In brief, 50 ng of comple-
mentary RNA of human KCNQ1 (NM_000218), human KCNE1
(NM_000219), rabbit KCNQ1 (NM_008252197.2), and rabbit KCNE1
(NM_001109822) were injected into defolliculated Xenopus oocytes (at a
3:1 KCNQ1/KCNE1 ratio for co-expression). Xenopus oocytes were
recorded in the two-electrode voltage-clamp configuration using a Dagan
CA-1B high-performance oocyte clamp amplifier (Dagan, MN, USA).
Control or DHA-supplemented control solutions (2–20 mM) were per-
fused extracellularly to the oocyte chamber using a Minipuls 3 peristaltic
pump (Gilson, WI, USA) with a perfusion rate of 1 mL/min. Solution was
perfused until a stable effect on current amplitude was observed (about
5–10 min of perfusion). Electrophysiological recordings were obtained
using Clampex 10.7 software (Molecular Devices, CA, USA).
Measurements were performed with a holding voltage of 80 mV fol-
lowed by test voltages ranging 90 to þ80 mV for 5 s each in 10 mV
increments, followed by a tail voltage to20 mV. The DHA effect on the
maximum conductance (V50) and maximal conductance (Gmax) and the
relative current at 0 mV was determined as previously described.13
In silico modelling
Computational simulations of single cells and tissue strands were per-
formed using the electrophysiological rabbit cardiomyocyte model by
Shannon et al.eRef1 Model parameters gKs and gKr (maximum conductances
of IKs and IKr) were adjusted to obtain APD90 values consistent with
APD90 measured in Langendorff-perfused hearts of WT and LQT2 rab-
bits14 instead of isolated WT cardiomyocytes as in the original model. As
IKr is absent in LQT2 cardiomyocytes harbouring the KCNH2-G628S
loss-of-function mutation,8 in LQT2 models, gKr was set to 0 mS/cm
2 and
gKs was fitted to be consistent with APD90 in LQT2 hearts. DHA effects
on (human and rabbit) KCNQ1/KCNE1 IKs were included into the LQT2
model by increasing gKs to 200%, in accordance with the patch clamp
data.
To quantify DHA effects on the cellular repolarization reserve, we
conducted single-cell simulations, in which we additionally varied gKs and
gCa, L (the maximum conductance of L-type calcium channel) in the range
of 0–100% and 100–500%, respectively. These changes are designed to
increase likelihood of pro-arrhythmic behaviour, such as early afterdepo-
larizations (EADs), n: 1 blocks, or permanent depolarization.eRef2 For
each model variant and at different pacing frequencies, we quantified,
which fraction of the parameter space produced pro-arrhythmic APs or
blocks.
Statistics
All data that support the findings of this study are available from the cor-
responding author upon reasonable request. Data are expressed as mean
± standard error of the mean (SEM). Statistical and Power analyses were
performed by Prism 8.0 (Graphpad, San Diego, CA, USA), Microsoft
Excel 2016 (Microsoft Corporation, Redmond, WA, USA), and Prism
StatMate. Graphs were created by Prism 8.0. After verification of normal
distribution, comparisons between different genotype groups were per-
formed using one-way ANOVA. Comparisons between values recorded
before and after DHA administration within the same groups were car-
ried out using two-tailed paired Student’s T-tests. The acceptable maxi-
mal a error was set at 5%.
Results
Docosahexaenoic acid activates human
and rabbit KCNQ1/KCNE1 channels
expressed in Xenopus oocyte
Docosahexaenoic acid-induced activation of human KCNQ1 alone is
observed as a shifted voltage dependence of channel opening (DV50)
towards more negative voltages (Figure 1A) and an increased Gmax
(Figure 1B).13,14 While DHA did not shift V50 of human KCNQ1/
KCNE1, (Figure 1D), DHA increased Gmax of human KCNQ1/KCNE1
(Figure 1E) to a larger extent. The total activating effect of DHA,
caused by the combined effect of shifting the V50 and increasing the
Gmax, at a voltage close to the systolic plateau voltage during a cardiac
AP can be estimated by quantifying the relative increase in Kþ current
(IDHA/ICtrl) at 0 mV.
eRef3 On average, for human KCNQ1 alone the rel-
ative increase of IDHA/ICtrl was 1.3 ± 0.09 (n = 6) for 20mM of DHA
(Figure 1C), while it was larger for human KCNQ1/KCNE1 with IDHA/
ICtrl of 2.0± 0.6 (n = 4) for 20mM of DHA (Figure 1F, data from Ref.
13).
Similar experiments on rabbit KCNQ1/KCNE1 expressed in
Xenopus oocytes showed that DHA shifts V50 towards more negative
voltages (Figure 1G), increases Gmax (Figure 1H), and increases the rel-
ative Kþ current IDHA/ICtrl at 0 mV (Figure 1I) by 2.1± 0.2 (n = 7) for
20mM of DHA. Altogether, the data summarized in Figure 1 show
that DHA activates human KCNQ1, human KCNQ1/KCNE1 and
rabbit KCNQ1/KCNE1, with the largest activating effect at a physio-
logically relevant voltage for the cardiac plateau phase for the two
KCNQ1/KCNE1 channels and with less effect on human KCNQ1
channels.











The average heart rate was similar in animals from the different geno-
types (RR-intervals, WT: 253 ± 19 ms; LQT1: 264 ± 6.2 ms; LQT2:
259 ± 17 ms; LQT2–5: 272 ± 39 ms; and LQT5: 272 ± 39 ms).
The average heart-rate corrected QTc interval duration, however, dif-
fered between WT and transgenic LQTS rabbit models (Figure 2A). In
line with previous data,9,10 LQT1, LQT2, and LQT2–5 rabbits showed a
significantly longer QTc than WT rabbits (all P-values < 0.01), while
LQT5 rabbits did not show any QT changes compared with WT. As the
QT prolongation was particularly pronounced at slower heart rates, the
QT/RR ratio was steeper in LQT2 and LQT2–5 rabbits than in WT con-
trols (P-values < 0.001) (Supplementary material online, Figure S1A).
Baseline ex vivo recordings on
Langendorff-perfused isolated rabbit
hearts
At a stimulation rate of 2 Hz, mean left ventricular APD75 recorded in
WT rabbit hearts was 135.0± 7.02ms. In transgenic LQTS rabbits, mean
APD75 was longer only in LQT2 rabbit hearts (LQT2, 162.3± 7.44ms,
DAPD75 compared with WT,þ27.2± 7.01ms, P-value = 0.022). No dif-
ference was found in mean APD75 of LQT1 (mean APD75 =
Figure 1 Effect of DHA on human and rabbit KCNQ1/KCNE1 channel expressed in Xenopus oocytes. Effect of 2–20 mM of DHA on V50 (A), Gmax
(B), and the current at 0 mV (C) for human KCNQ1. All data are presented as mean ± SEM. n = 3–6 depending on concentration. (D–F) Same as in
(A–C) but for human KCNQ1/KCNE1. All data are presented as mean ± SEM. n = 4. (G–I) Same as in (D–F) but for rabbit KCNQ1/KCNE1. All data
are presented as mean ± SEM. n = 7. (Data presented in panels A, D, E, and F have been previously published in Refs.12,13.) DHA, docosahexaenoic
acid;KCNE1, b-subunit to IKs-conducting potassium channel; KCNQ1, a-subunit to IKs-conducting potassium channel; SEM, standard error of the
mean.
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131.9± 4.92 ms), LQT2–5 (mean APD75 = 144.3± 6.07 ms), or LQT5
rabbit hearts (mean APD75 = 120.7± 4.59 ms) compared with WT rab-
bit hearts (Figure 2B), similarly as in previous studies.10,eRef4 AP triangula-
tion—a marker for the prolongation of phase 3 repolarization—was
more pronounced in LQT2 and LQT2–5 than in WT rabbit hearts
(WT: 75.2± 2.34ms; LQT2: 103.8± 2.83ms, P-value < 0.001 vs. WT;
and LQT2–5: 91.5± 3.39ms, P-value = 0.002 vs. WT; Figure 2C). No sig-
nificant differences in AP triangulation were apparent between LQT1,
LQT5, and WT rabbits.
Effects of docosahexaenoic acid on
telemetric ECG in conscious rabbits
In LQT1 rabbits, DHA administration shortened mean RR intervals
from 264.0± 6.24 to 235.5± 5.00 ms (P-value = 0.006), thus inducing
a slight increase in average heart rate. In all other genotypes only mar-
ginal, non-significant changes in RR interval were observed.
Docosahexaenoic acid influenced cardiac repolarization in a
genotype-specific fashion: In WT and—more pronouncedly—in LQT2
rabbits, DHA shortened the absolute QT and heart-rate corrected
QTc intervals (DQTc: WT, 12.0± 1.88 ms, P-value = 0.001; LQT2,
20.7± 1.71 ms, P-value < 0.001), while no changes were observed in
LQT1, LQT5, and LQT2–5 rabbits, whose IKs-function is impaired
(Figure 3A and B). Important to note, this QTc-shortening effect in WT
and LQT2 rabbits was seen in each individual rabbit (Figure 3D).
In LQT2 rabbits, the QT shortening effect of DHA could be seen
at all heart rates and flattened the QT/RR ratio curve (P-value = 0.01)
(Supplementary material online, Figure S1B).
To investigate whether DHA may normalize the prolonged QTc
to physiological values, we compared QTc of transgenic LQTS rab-
bits following DHA administration to QTc of WT rabbits at baseline
(Figure 3C). DHA administration normalized QTc in LQT2 rabbits
completely (P-value for difference between WT and LQT2 þ DHA
= 0.950). QTc intervals in LQT1 and LQT2–5 rabbits, in contrast,
Figure 2 Baseline electrical differences between different LQTS genotypes in vivo and ex vivo. (A) Heart-rate corrected QTc interval. (B) Action po-
tential duration at 75% of repolarization. (C) Action potential triangulation in transgenic LQT1. (D) Short-term variability of QT. (A–D) LQT1: green,
in vivo n = 8, ex vivo n = 7; LQT2: red, in vivo n = 6, ex vivo n = 6; LQT2–5: violet, in vivo n = 8, ex vivo n = 9; and LQT5: blue, in vivo n= 8, ex vivo n = 9; WT
littermates: grey, in vivo n = 6, ex vivo n = 7. Differences are indicated as * for P-value < 0.050, ** for P-value < 0.010, and *** for P-value < 0.001. All
data are presented as mean ± SEM. The WT (grey) bars are shown next to each LQTS genotype bar to better indicate the difference to WT for each
individual genotype. LQTS, long QT syndrome; LQT1, long QT Type 1; LQT2, long QT Type 2; LQT5, long QT Type 5; LQT2–5, combined form of
long QT Types 2 and 5; SEM, standard error of the mean; WT, wild type.
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remained prolonged after DHA administration (LQT1, P-value =
0.003; LQT2–5, P-value = 0.008). In LQT5 rabbits without any overt
QT prolongation, QTc remained unchanged after DHA.
Effects of docosahexaenoic acid on 12-
lead ECG in anaesthetized rabbits
Docosahexaenoic acid administration accelerated heart rate (short-
ened RR interval) only in LQT1 (RRbaseline: 347.42 ± 17.04 ms,
RRDHA: 371.75± 17.37 ms, P-value < 0.001) and not in the other ge-
notype groups. DHA had no effects on PR or QRS in any of the
genotypes.
After intravenous administration of DHA in anaesthetized rabbits,
a statistically significant shortening of QTc was observed in WT
(DQTc: 7.31 ± 1.52 ms, P-value = 0.005) and in LQT2 (DQTc:
11.35± 1.77 ms, P-value = 0.003), while no changes of QTc were
observed in LQT1, LQT2–5, and LQT5 rabbits (Supplementary ma-
terial online, Figure S2A).
At baseline, temporal QT variability [characterized by the short-term
variability of QT interval (STVQT)] was significantly higher in LQT2 rab-
bits compared with LQT1 or WT rabbits (baseline STVQTLQT2:
8.46± 1.90ms, baseline STVQTLQT1 3.45± 0.32ms, baseline STVQTWT
4.75± 1.00ms; One-way ANOVA P-value = 0.036) (Figure 2D). Due to
a significant reduction of STVQT upon DHA-infusion in LQT2 rabbits
(DSTVQT LQT2:2.33± 0.58ms, P-value = 0.016), after 20min adminis-
tration of DHA STVQT was similar in all genotypes (one-way ANOVA
P-value = 0.566), indicating a normalization of STVQT in LQT2
(Figure 4A–C and Supplementary material online, Figure S3).
Figure 3 Effects of DHA on QT interval in vivo in telemetric ECGs. (A) Representative examples of telemetric ECGs recorded in WT, LQT1,
LQT2, LQT2–5, and LQT5 rabbits before (above) and after (below) administration of DHA. Q and the end of the T-wave are indicated with vertical
lines. (B) Left panel: QTc comparison before (fully coloured columns) and after (dotted columns) administration of DHA in WT, LQT1, LQT2,
LQT2–5, and LQT5 rabbits. Right panel: changes in QTc in the different genotypes are indicated as DQTc. (C) Comparison of QTc in LQTS rabbits
treated with DHA vs. baseline QTc in WT animals (grey), indicates a normalization in LQT2 (lack of differences between LQT2þDHA and WT at
baseline). Grey bars are repeated to better show the difference to WT for each individual genotype. (D) Representation of DHA-induced QTc
changes in the individual rabbits (left: QTc values before and right: after administration of DHA). (B–D) Sample numbers: LQT1 (green) n = 8, LQT2
(red) n = 6, LQT2–5 (violet) n = 8, LQT5 (blue) n = 8, and WT rabbits (grey) n = 6. Differences are indicated as * for P-value < 0.050, ** for P-value <
0.010, and *** for P-value < 0.001. All data are presented as mean ± SEM. DHA, docosahexaenoic acid;LQTS, long QT syndrome; LQT1, long QT
Type 1; LQT2, long QT Type 2; LQT5, long QT Type 5; LQT2–5, combined form of long QT Types 2 and 5; SEM, standard error of the mean; WT,
wild type.
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Spatial QT dispersion neither showed relevant genotype-related dif-
ferences at baseline nor was it significantly influenced by DHA in any of
the genotype groups (Supplementary material online, Figure S2B).
Effects of docosahexaenoic acid in
perfused whole hearts ex vivo
Docosahexaenoic acid shortened mean APD75 in WT (DAPD75:
12.3± 2.22 ms, P-value < 0.001) and LQT2 rabbits (DAPD75:
18.1± 3.54 ms, P-value = 0.004) (Figure 5A–B). The DHA-shortening in
LQT2 was so pronounced that in LQT2 hearts perfused with DHA no
longer any prolongation of APD75 was observed in comparison to WT
hearts at baseline conditions (APD75-LQT2-DHA: 144.12± 5.50 ms,
APD75-WT: 135.03± 7.02ms, T-test P-value = 0.342), indicating a DHA-
induced normalization of APD75 in LQT2 (Figure 5C). Importantly, the
APD-shortening effect of DHA in WT and LQT2 rabbits was seen in
each individual rabbit (Figure 5D). No relevant changes of the APD75
were recorded in LQT1, LQT2–5, or LQT5 rabbit (Figure 5A–B).
We further analysed whether DHA’s APD75-shortening effects in
LQT2 and WT rabbits differed in the various LV regions. At 2 Hz
pacing rate, APD75 shortening effects were observed in both LQT2
and WT rabbits in the LV mid-lateral wall and in LV lateral base regions.
However, only in WT but not in LQT2 rabbits APD75-shortening was
also significant at the LV apex and LV medial base regions (Figure 6A).
Notably, spatial APD75 dispersion was not altered by DHA neither in
WT nor in LQT2—similarly as observed with QT dispersion.
Action potential triangulation was significantly reduced after DHA
administration only in LQT2 rabbits (from baseline 103.8 ± 2.83 to
96.9 ± 2.41 ms; P-value < 0.001; Figure 6B), though not in WT, LQT1,
LQT2–5, or LQT5 rabbits. Despite its reduction, in DHA-treated
LQT2 rabbits AP triangulation remained more elevated than in WT
rabbits at baseline (Figure 6C).
Effects of docosahexaenoic acid on action
potential duration and arrhythmogenesis
in silico
The modelled APs (Figure 7A) demonstrate a longer APD in LQT2
than in WT and a pronounced DHA-induced shortening of APD in
LQT2, supporting our experimental observations. Single-cell
Figure 4 Effects of DHA on STVQT in vivo. (A) Representative examples of short term variability of QT measured in WT and LQT2 rabbits before
(left) and after (right) administration of DHA. (B) Histograms showing STVQT before (fully coloured columns) and after (dotted columns) administra-
tion of DHA in WT, LQT1, LQT2, LQT2–5, and LQT5 rabbits. Differences are indicated with * for P-value < 0.050. All data are presented as mean ±
SEM. (C) Histograms showing a comparison between STVQT in transgenic LQTS rabbits treated with DHA vs. baseline STVQT in WT animals
(grey); a normalization in LQT2 can be observed (lack of significant differences between LQT2þDHA and WT at baseline). Differences are indicated
as * for P-value <0.050, and as ** for P-value <0.010. All data are presented as mean ± SEM. Grey bars are repeated to better show the difference to
WT for each individual genotype. DHA, docosahexaenoic acid; LQTS, long QT syndrome; LQT1, long QT Type 1; LQT2, long QT Type 2; LQT5,
long QT Type 5; LQT2–5, combined form of long QT Types 2 and 5; STVQT, short-term variability of QT interval; SEM, standard error of the mean;
WT, wild type.







niversity of Szeged user on 06 O
ctober 2021
simulations with varied conductivities of gKs and gCa,L aiming at quanti-
fying (potential positive) DHA effects on the cellular repolarization
reserve were performed. The analysis of the parameter space of gKs
and gCa,L revealed that the LQT2 model produce EAD, blocks, and
permanent depolarization for many more combinations of parame-
ters than the WT model (Figure 7B for pacing at 1.0–2.5 Hz,
Supplementary material online, Figure S4 for pacing at 1.0–4.5 Hz),
and importantly, that DHA exerted an anti-arrhythmic effect by re-
ducing these arrhythmogenic AP compared with LQT2, reaching a
level very close to WT cells. Figure 7C shows the prevalence for
arrhythmogenic behaviour over all tested pacing frequencies,
expressed as the ratio of parameter combinations that do not result
in EAD, blocks, or permanent depolarization, compared with WT at
1 Hz. Again, LQT2 þ DHA cells had consistently lower arrhythmic
behaviour than LQT2 cells over all frequencies, nearly reaching the
level of WT cells, particularly at faster stimulation frequencies.
Discussion
In this study, we investigated the potential beneficial APD/QT-
shortening effects of the IKs-activator DHA, a natural polyunsaturated
fatty acid (PUFA),5 in vivo and ex vivo on the whole heart level in four
different transgenic rabbit models of LQTS.
In WT and more pronouncedly in transgenic LQT2 rabbit models,
DHA significantly shortened QTc and reduced the beat-to-beat vari-
ability of repolarization, quantified as STVQT in vivo, and shortened
APD75 and reduced AP triangulation ex vivo. Notably, in LQT2 rabbits
the effect of DHA led to a normalization of QTc, STVQT, and APD75
to the level observed in healthy WT rabbits, suggesting that DHA
may exert a beneficial therapeutic effect in LQT2.
Several experimental studies have investigated the effects of differ-
ent PUFAs on cardiac electrophysiology. We have chosen DHA,
which increased the magnitude of IKs current in KCNQ1/KCNE1-
Figure 5 Effects of DHA on action potential duration ex vivo. (A) Representative examples of recorded MAPs before (in grey) and after administra-
tion of DHA in perfused WT (black), LQT1 (green), LQT2 (red), LQT2–5 (violet), and LQT5 (blue) rabbit hearts. The APD shortening appears during
phase 3, which corresponds to the phase in which IKs is conducted. (B) Left panel: APD75 in WT, LQT1, LQT2, LQT2–5, and LQT5 rabbits before and
after DHA administration. Right panel: changes in APD75 in the different genotypes are indicated as DAPD75. (C) Comparison of APD75 in LQTS rab-
bits treated with DHA vs. baseline QTc in WT animals (grey) indicates a normalization in LQT2 (lack of differences between LQT2þDHA and WT
at baseline). Grey bars are repeated to better show the difference to WT for each individual genotype. (D) Representation of DHA-induced APD75
changes in the individual rabbits (left: APD75 values before; right: after administration of DHA). (B–D) Sample numbers: LQT1 (green) n = 7, LQT2
(red) n = 6, LQT2–5 (violet) n = 9, LQT5 (blue) n = 9, and WT rabbits (grey) n = 7. Differences are indicated as * for P-value < 0.050, ** for P-value <
0.010, and *** for P-value < 0.001. All data are presented as mean ± SEM. DHA, docosahexaenoic acid; LQTS, long QT syndrome; LQT1, long QT
Type 1; LQT2, long QT Type 2; LQT5, long QT Type 5; LQT2–5, combined form of long QT Types 2 and 5; MAP, monophasic action potential; SEM,
standard error of the mean; WT, wild type.
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transfected COS7 cells and in guinea pig cardiomyocytes more than,
for example, eicosapentaenoic acid, another omega-3 fatty acid of
marine origin. These findings have been further supported by the
groups of Liin, Bentzen, and Larsson,4,6,12 who have observed that
natural and modified PUFAs activate the IKs-conducting channel
through a lipoelectric interaction between the negatively charged
PUFA head group and positively charged aminoacidic residues in the
alpha-subunit KCNQ1.
Along this line, they also described a significant shortening of the
prolonged QT and prolonged APD in a guinea pig model of drug-
induced LQTS.9 Our results confirm this observation of QT/APD-
shortening in wild-type rabbits—and importantly—in transgenic
LQTS rabbit models. Moreover, as we used several different trans-
genic rabbit models for different LQTS subtypes, in which different al-
pha- and beta-subunits of repolarizing ion channels are impaired
(namely, KCNQ1 in LQT1, KCNH2 in LQT2, KCNE1 in LQT5, and
KCNQ1 and KCNE1 in LQT2–5), important information regarding
the mechanistic action of DHA on IKs could be obtained.
Moreno et al.5 suggested that the DHA-induced acceleration of
ventricular repolarization was based on a modification of the
Figure 6 Effects of DHA on regional APD and AP triangulation ex vivo. (A). Effects of DHA on APD75 in apex, mid lateral wall, lateral basis, and me-
dial basis in WT, LQT1, LQT2, LQT2–5, and LQT5 rabbits. (B) AP triangulation before (fully coloured columns) and after (dotted columns) adminis-
tration of DHA in WT, LQT1, LQT2, LQT2–5, and LQT5 rabbits. (C) Comparison between APD75 in LQTS rabbit hearts after administration of
DHA and AP triangulation in WT rabbit hearts before administration of DHA. In contrast to QTc and APD75, a normalization of AP triangulation can-
not be observed in LQT2 after DHA administration; sample numbers: LQT1 (green) n = 7, LQT2 (red) n = 6, LQT2–5 (violet) n = 9, LQT5 (blue)
n = 9, and WT rabbits (grey) n = 7. Differences are indicated as * for P-value < 0.050, ** for P-value < 0.010, and *** for P-value < 0.001. All data are
presented as mean ± SEM. AP, action potential; APD, action potential duration; DHA, docosahexaenoic acid; LQTS, long QT syndrome; LQT1, long
QT Type 1; LQT2, long QT Type 2; LQT5, long QT Type 5; LQT2–5, combined form of long QT Types 2 and 5; MAP, monophasic action potential;
SEM, standard error of the mean; WT, wild type.
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interaction between the alpha- and beta-subunits KCNQ1 and
KCNE1 that leads to an enhancement of IKs current. Accordingly, IKs-
activating effects of DHA could not be observed, when KCNQ1
channels were expressed alone,5 suggesting that the presence of
functional KCNE1 subunits was essential for the observed electro-
physiological DHA-effects. We now demonstrated in Xenopus oo-
cyte experiments that DHA activates human KCNQ1, human
KCNQ1/KCNE1 and rabbit KCNQ1/KCNE1 IKs to different extents,
with the largest activating effect in the two KCNQ1/KCNE1 channels
and with less effect on human KCNQ1 channels (when the beta-
subunit KCNE1 is missing), indicating an importance of both subunits
for a pronounced DHA-induced IKs activation. The larger relative in-
crease in Kþ current at 0 mV for human KCNQ1/KCNE1 compared
with KCNQ1 can be largely explained by the different voltage depen-
dence of the two channels. Half maximal conductance is reached at
aboutþ20 mV for human KCNQ1/KCNE1 and at about30 mV for
KCNQ1,eRef5 which means that at 0 mV KCNQ1 has already
approached its maximal conductance, giving less possibility for DHA
to induce combined activating effects. In line with these hypotheses,
no QT/APD-shortening effects were observed neither in LQT5 and
LQT2–5 rabbits with impaired KCNE1-subunits nor in LQT1 rabbits
with impaired KCNQ1—while pronounced QT/APD-shortening
effects were observed in LQT2 and WT with intact KCNE1 and
KCNQ1 function. This strongly suggests that DHA may exert a
genotype-specific beneficial effect only in LQTS subtypes with intact
IKs function.
Recently, possible PUFA interaction sites have been identified at
the voltage-sensor and the pore region of the KCNQ1 channel, using
coarse-grained and all-atom molecular dynamics simulations.15
Although DHA is a protonable PUFA, which allows it to cross the
Figure 7 In silico modelling of DHA effects. (A) Simulated APs at 2 Hz based on Shannon model for WT, LQT2 (gKr = 0%), and LQT2þDHA (gKs
þ100%) cardiomyocytes. (B) Results of single-cell in silico simulations for combinations of parameters gKs and gCa, L at 1.0–2.5 Hz. Every square repre-
sents one simulation. Shaded squares represent parameters where pacing was successful (shade encodes APD90). Pink and purple squares represent
simulations where 2:1 block and EAD occur, respectively. Black squares represent simulations where the cell was unable to repolarize. Numbers in
bottom right corners of each plot indicate simulations resulting in block, EAD or permanent depolarization. (C) Normalized repolarization reserve cal-
culated from the number of single-cell pacing simulations in the parameter space 0 < gKs/gKs,orig < 1 (step 0.1) and 1 < gCaL/gCaL,orig < 5 (step 0.2) that
did not result in EAD, block or permanent depolarization. Reference for normalization is the number of simulations for WT at 1 Hz that did not show
these pro-arrhythmic features. AP, action potential; DHA, docosahexaenoic acid; EAD, early after depolarization; LQT2, long QT Type 2; WT, wild
type.
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cell membrane and to exert effects through intracellular or extracel-
lular interactions, the functional PUFA sites in KCNQ1 seem to be lo-
cated in the outer membrane leaflet.15 Along those lines, it is
important to note, that the KCNQ1 mutation expressed in our trans-
genic LQT1 rabbit models is a dominant negative pore mutation with
complete loss of functional IKs, in which no DHA-induced APD short-
ening can be expected. This may of course be different in other
KCNQ1 variants in other regions of the gene and raises the possibil-
ity that some clinically relevant mutations may influence the DHA ef-
fect (e.g. when located in PUFA-interacting regions); and in some
LQT1 variants one might still see some DHA-induced rescue of the
phenotype. Hence, it is very important to stress that DHA may—in
addition to the genotype-specific beneficial DHA effect in LQTS gen-
otypes with normal KCNQ1 and KCNE1 function—also have
mutation-specific beneficial effects in some LQT1 and/or LQT5
mutations.
The fact that not only global QTc and APD were shortened/nor-
malized by DHA in LQT2 rabbits but also classical in vivo and ex vivo
pro-arrhythmia markers such as STVQT and AP triangulation, sug-
gests that DHA might also exert anti-arrhythmic effects. STVQT,
which characterizes temporal instability in cardiac repolarization, has
been validated as a novel marker regarding arrhythmic risk also in hu-
man LQTS16—and it was also most pronounced in transgenic LQT2
rabbits with the highest risk for spontaneous TdP arrhythmias.8,10
Importantly, DHA normalized STVQT to the level observed in WT
rabbits, strongly suggesting that not only overall cardiac repolariza-
tion was stabilized but also the pro-arrhythmic temporal instability of
repolarization was reduced. Similarly, the arrhythmogenicity marker
AP triangulation, which is particularly increased in LQT2 rabbits with
a marked pro-arrhythmic phenotype,8,10 was also reduced by DHA
in LQT2. The failure to normalize AP triangulation completely may
be due to the fact that the extent of AP triangulation is strongly de-
pendent on IK1 and IKr, and somewhat less on IKs.
17
To further investigate potential anti-arrhythmic effects of DHA in
LQT2, we have conducted in silico modelling experiments incorporat-
ing the observed DHA-induced increase in IKs. In these we identified a
reduction in EAD formation and in 2:1 blocks as well as an improved
repolarization reserve in LQT2 cells with shortened APD due to an
increase in IKs byþ100% that corresponds to the experimentally ob-
served DHA-effect on IKs. Despite such encouraging evidence, the
potential anti-arrhythmic effects certainly need to be validated in
larger, long-term studies directly investigating DHA-effects on spon-
taneous (and provoked) TdP ventricular arrhythmias and SCD in
LQTS.
In both WT and in LQT2 rabbits, an APD-shortening was ob-
served in all investigated left ventricular regions, despite not reaching
statistical significance in the apex and in the medial base in LQT2.
This may be the reason why DHA had no effect on APD dispersion
and—particularly—did not increase APD dispersion. This is impor-
tant as it has previously been shown that the activation of one specific
potassium channel may exert pro-arrhythmic effects by increasing
the dispersion of repolarization or by causing excessive regional
APD-shortening effects, because of underlying regional heterogeneity
in the expression of cardiac potassium channels.18 Why the pharma-
cological activation of IKr increased APD dispersion,
18 while the
activation of IKs by DHA did not, is currently unclear. One might spec-
ulate that the underlying regional differences in IKs and IKr that are
unmasked by the activation of the reciprocal current might differ in
their extent. The fact that DHA also affects other channel proteins,
such as voltage-gated Naþ and Ca2þ channels that are heteroge-
neously expressed throughout the ventricles may counteract some
of the regional effects of IKs activation. DHA effects on other (un-
known) protein that alter excitability in pacemaker cells which coun-
teract the decrease in excitability by DHA’s activating effect on IKs,
might also underlie the observation that DHA impacts on heart rate
in LQT1 but not in WT and LQTS rabbits with intact IKs.
As rabbits show pronounced similarities to humans in terms of
cardiac electrophysiology, and—particularly—as the transgenic
LQTS rabbits mimic all major aspects of the human LQTS disease
phenotypes, it stands to reason that the observed beneficial DHA
effects in LQT2 rabbits could have a translational impact on future
genotype-specific treatment approaches in LQTS. Thus far, no stud-
ies have investigated DHA effects in human LQTS patients.
Moreover, the available literature offers only limited data regarding
the effects of PUFA and more specifically of DHA on cardiac electro-
physiology—as the focus of these studies was more on prevention of
cardiovascular diseases—where PUFA supplementation seems to be
beneficial.19,eRef6 Recently, though, Yagi et al.20 observed that low lev-
els of DHA were associated with cardiogenic syncope in patients af-
fected by Brugada syndrome, suggesting that DHA may play an
important role in preventing ventricular fibrillation in this cohort of
patients. Our observations in transgenic LQTS rabbit models may
open the door for a translational, clinical evaluation of DHA as novel
genotype-specific therapy in LQTS. To this aim, additional experi-
ments directly demonstrating anti-arrhythmic effects in animal mod-
els and—importantly—first confirmatory studies in human patients
are still warranted.
Conclusion
We demonstrated that DHA exerts a genotype-specific benefi-
cial shortening/normalizing effect on QTc, STVQT, APD75, and
AP triangulation through activation of IKs in LQT2 rabbits but has
no effects if either KCNQ1 (a-subunit to IKs) or KCNE1 (b-subu-
nits to IKs) are functionally impaired (as in LQT1, LQT5, and
LQT2–5). Thus, DHA could represent a new genotype-specific
therapeutic option in LQT2 syndrome (or other LQTS subtypes
with intact a- and b-subunits to IKs).
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